In Situ photoimmunotherapy for advanced cutaneous melanoma

Mark F. Naylor, Robert E. Nordquist, T. Kent Teaque, David A. Adelson, Lisa A. Perry, Wei R. Chen

Research output: Chapter in Book/Report/Conference proceedingConference contribution


Currently there are no truly effective treatments for advanced melanoma (surgically unresectable stage III and IV). In situ photoimmunotherapy (ISPI) is a recently developed therapy based on physical and immunological principles that uses lasers in combination with immunostimulants to achieve clinically significant responses in advanced melanoma patients. Results from an ongoing phase I clinical trial suggest that this form of therapy has the highest response rate of any treatment known for advanced melanoma, and in a significant number of subjects, periods of prolonged remissions from the disease can be achieved. ISPI is therefore clearly one of the most promising forms of therapy for this disease and better understanding of the immunological and physical parameters of this treatment will lead to even better clinical results.

Original languageEnglish (US)
Title of host publicationBiophotonics and Immune Responses III
StatePublished - 2008
Externally publishedYes
EventBiophotonics and Immune Responses III - San Jose, CA, United States
Duration: Jan 21 2008Jan 21 2008

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
ISSN (Print)1605-7422


OtherBiophotonics and Immune Responses III
Country/TerritoryUnited States
CitySan Jose, CA


  • Imiquimod
  • Immunotherapy
  • Laser
  • Melanoma
  • Solid tumor therapy

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Biomaterials
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'In Situ photoimmunotherapy for advanced cutaneous melanoma'. Together they form a unique fingerprint.

Cite this